Less than a year after investing heavily in Minnesota-based Anteris Technologies, Medtronic has announced a new strategic investment in Pi-Cardia. The TAVR technology at the heart of this investment is Pi-Cardia's FDA-approved ShortCut device. 

According to a new analysis of the STS/ACC TVT Registry, redo TAVR with a self-expanding transcatheter heart valve is associated with a strong safety profile and early outcomes comparable to traditional TAVR procedures.

TAVR can be especially challenging in patients with PAR and an enlarged LVOT. Specialists in China have developed a new technique that could improve outcomes for some of these patients without introducing new risks. 

Many patients who need TAVR also present with coronary artery disease. According to new data presented at ESC Congress 2026, performing TAVR first is noninferior to performing PCI first. 

As always, heart team discussions play a vital role when choosing between TAVR and SAVR for patients with large or extra-large aortic annuli. 

TAVR continues to gain momentum as a go-to treatment option. A group of experts convened at CRT 2026 to discuss where the field stands today and what questions remain unanswered. 

Treating asymptomatic patients with TAVR may cost more at first, but it appears to be a wise financial decision as time goes on.

Incidental lung findings can help identify TAVR patients who may require additional follow-up care after treatment. 

Predicting complications is one thing—the team behind this study hoped to anticipate when patients are more likely to see a minimal benefit from TAVR.